Analyst picks & changes

Company

Bank

Analyst

Coverage

Opinion

Wk chg

7/25 cls

Gilead Sciences Inc. (NASDAQ:GILD)

BMO Capital Markets

Jim Birchenough

Price target

Outperform

1%

$89.84

Birchenough raised his target to $165 from $123 on Gilead's strong 2Q14 results, continued strength of its HCV drug Sovaldi sofosbuvir and increased guidance. Last week, the company announced 2Q14 EPS and revenues that beat the Street's estimates. Gilead also updated its 2014 revenue guidance to reflect sales of Sovaldi and now expects $21-$23B, up from $11.3-$11.5B. Birchenough raised his 2014 EPS estimate from $5.98 to $7.35 and his 2015 EPS estimate from $6.25 to $8.38.